Scott M Norberg, Ke Bai, Cem Sievers, Yvette Robbins, Jay Friedman, Xinping Yang, Meg Kenyon, Elizabeth Ward, Jeffrey Schlom, James Gulley, Amy Lankford, Roshanak Semnani, Helen Sabzevari, Douglas E Brough, Clint T Allen
Recurrent respiratory papillomatosis (RRP) is a rare, debilitating neoplastic disorder caused by chronic infection with human papillomavirus (HPV) type 6 or 11 and characterized by growth of papillomas in the upper aerodigestive tract. There is no approved medical therapy, and patients require repeated debulking procedures to maintain voice and airway function. PRGN-2012 is a gorilla adenovirus immune-therapeutic capable of enhancing HPV 6/11-specific T cell immunity. This first-in-human, phase 1 study (NCT04724980) of adjuvant PRGN-2012 treatment in adult patients with severe, aggressive RRP demonstrates the overall safety and clinically meaningful benefit observed with PRGN-2012, with a 50% complete response rate in patients treated at the highest dose...
October 25, 2023: Science Translational Medicine